Adverse Events After XBB.1.5-Containing COVID-19 mRNA Vaccines.
作者信息
Andersson Niklas Worm, Thiesson Emilia Myrup, Hviid Anders
机构信息
Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
出版信息
JAMA. 2024 Mar 26;331(12):1057-1059. doi: 10.1001/jama.2024.1036.
Abstract
摘要
相似文献
1
Adverse Events After XBB.1.5-Containing COVID-19 mRNA Vaccines.
JAMA. 2024 Mar 26;331(12):1057-1059. doi: 10.1001/jama.2024.1036.
2
Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
J Infect Dis. 2024 Aug 16;230(2):e279-e286. doi: 10.1093/infdis/jiae067.
3
Effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine in Korea: interim analysis.
Front Immunol. 2024 May 13;15:1382944. doi: 10.3389/fimmu.2024.1382944. eCollection 2024.
4
Monitored COVID-19 mRNA vaccine second doses for people with adverse reactions after the first dose.
Allergy Asthma Proc. 2022 Jan 1;43(1):37-39. doi: 10.2500/aap.2022.43.210100.
5
Safety and Adverse Events Among Long-term Care Residents Receiving a Third COVID-19 mRNA Vaccine Booster Dose in Quebec.
JAMA Netw Open. 2022 Jul 1;5(7):e2223401. doi: 10.1001/jamanetworkopen.2022.23401.
6
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
Lancet Respir Med. 2023 Dec;11(12):1089-1100. doi: 10.1016/S2213-2600(23)00306-5. Epub 2023 Oct 25.
7
The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.
Immunotherapy. 2022 Feb;14(2):91-94. doi: 10.2217/imt-2021-0235. Epub 2021 Nov 8.
8
Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.
BMJ. 2022 Jul 13;378:e070483. doi: 10.1136/bmj-2022-070483.
9
Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study.
Int J Rheum Dis. 2022 Mar;25(3):353-363. doi: 10.1111/1756-185X.14279. Epub 2022 Jan 3.
10
Myocarditis in Three Japanese Men After the Second mRNA-Based COVID-19 Vaccine Dose.
Am J Ther. 2024;31(1):e93-e96. doi: 10.1097/MJT.0000000000001562. Epub 2022 Aug 26.
引用本文的文献
1
Safety of JN.1-Updated mRNA COVID-19 Vaccines.
JAMA Netw Open. 2025 Jul 1;8(7):e2523557. doi: 10.1001/jamanetworkopen.2025.23557.
2
Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study.
Nat Commun. 2025 Jul 15;16(1):6514. doi: 10.1038/s41467-025-61613-4.
3
Genome diversity of SARS-CoV-2 lineages associated with vaccination breakthrough infections in Addis Ababa, Ethiopia.
BMC Infect Dis. 2025 May 23;25(1):738. doi: 10.1186/s12879-025-11107-x.
4
Active Surveillance for Safety Monitoring of XBB.1.5-Containing COVID-19 mRNA Vaccines in Korea.
J Korean Med Sci. 2024 Nov 11;39(43):e309. doi: 10.3346/jkms.2024.39.e309.
5
Navigating the Evolving Landscape of COVID-19: Strategies to Increase Vaccine Confidence and Improve Vaccination Rates in the United States.
Vaccines (Basel). 2024 Sep 19;12(9):1072. doi: 10.3390/vaccines12091072.
6
Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact Analysis.
Infect Dis Ther. 2024 Oct;13(10):2155-2177. doi: 10.1007/s40121-024-01032-y. Epub 2024 Sep 10.
7
Pericardial Diseases Mortality Trends in Brazil From 2000 to 2022.
Cureus. 2024 Apr 10;16(4):e57949. doi: 10.7759/cureus.57949. eCollection 2024 Apr.
Zotero 插件